DIM
CSTL icon

DC Investments Management’s Castle Biosciences CSTL Stock Holding History

DC Investments Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-28,038
Closed -$507K – 257
2019
Q3 		$507K Buy
+28,038
New +$622K 0.29% 127

Other funds holding CSTL

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

DC Investments Management's CSTL Position: Q4 2019 in Review

DC Investments Management sold out of Castle Biosciences (CSTL) in Q4 2019, closing a stake of 28,038 shares — an estimated $507K sold.

DC Investments Management first reported a position in CSTL in Q3 2019 and held it in 1 quarter. The position peaked at $507K in Q3 2019. 67 funds tracked by Wall St. Rank hold CSTL as of Q4 2019.

  • DC Investments Management reported no remaining Castle Biosciences position as of Q4 2019 after selling out during the quarter.
  • DC Investments Management sold 28,038 Castle Biosciences shares in Q4 2019, an estimated $507K.
  • DC Investments Management first reported a position in Castle Biosciences in Q3 2019 and held it in 1 quarter.
  • DC Investments Management's Castle Biosciences position peaked at $507K in Q3 2019.
  • 67 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2019.

Based on DC Investments Management's 13F filing for Q4 2019, filed 7 Feb 2020.